The American Heart Association will honor Dr. Annet Kirabo, D.V.M., Ph.D., FAHA, with the 2026 Joseph A. Vita Award at its Scientific Sessions 2026, to be held Nov. 6-9 in Chicago. The award recognizes a scientist whose research has significantly advanced cardiovascular biology or health within the past five years and whose work has been published in the Association's journals. Dr. Kirabo, a professor of medicine at Vanderbilt Health, is internationally recognized for demonstrating how immune activation and inflammation contribute to high blood pressure, a finding that has reshaped the understanding of hypertension.
Her research showed that lipid oxidation-derived protein adducts act as neoantigens that trigger antigen-presenting cell activation, T-cell responses, vascular dysfunction, and hypertension. These discoveries, detailed in studies such as those published in the Journal of the American Heart Association, fundamentally changed how scientists view blood pressure regulation. The award, named after the late Joseph A. Vita, M.D., founding editor of JAHA, is selected by the editors-in-chief of the Association's 14 peer-reviewed journals and celebrates research that transforms cardiovascular science.
Manesh R. Patel, M.D., FAHA, the Association's 2026-2027 volunteer president, said, "Dr. Annet Kirabo exemplifies the spirit of the Joseph A. Vita Award, which recognizes research that changes the direction of cardiovascular science. Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease." He noted that her work has uncovered potential therapeutic targets, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways in immune cells, opening exciting possibilities for preventing and treating hypertension and related cardiovascular and kidney diseases.
Dr. Kirabo's laboratory now combines immunology, vascular biology, genomics, metabolomics, and single-cell technologies to identify new therapeutic strategies. With more than 230 scientific publications and sustained NIH funding, her work continues to influence investigators worldwide. She has also been an active Heart Association volunteer since 2009, serving on the Council on Hypertension Communications Committee and as an associate editor of Circulation Research since 2019. In addition, she has served on the editorial board of the Hypertension journal since 2018.
"I am deeply honored to receive the Joseph A. Vita Award from the American Heart Association, an organization that has supported my career from my predoctoral and postdoctoral fellowships through my development as an independent investigator," said Dr. Kirabo. "Scientific discovery, mentorship and advancing new treatments for cardiovascular disease have been the primary focus of my career, and it is both rewarding and humbling to be recognized for it."
The implications of this award extend beyond recognition. Dr. Kirabo's work has opened new frontiers in cardiovascular research, highlighting the immune system as a key player in hypertension. Her findings suggest that targeting immune pathways could lead to novel treatments for high blood pressure, a condition affecting millions worldwide. As the recipient of the 2026 Joseph A. Vita Award, she joins a distinguished group of scientists whose work has fundamentally altered the course of cardiovascular science. The award will be presented during the Opening Session on Saturday, Nov. 7. Additional resources, including multimedia, are available on the release link.
